dual payload ADC

The Rise of Dual Payload ADCs/PDCs: A Comprehensive Overview of Research and Development

by
The Rise of Dual Payload ADCs/PDCs: A Comprehensive Overview of Research and Development

Introduction The emergence of dual payload antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs) marks a significant evolution in the field of targeted therapy. 01 Background Antibody-drug conjugates (ADCs) have garnered attention for their ability to deliver cytotoxic agents precisely to cancer cells, earning them the title of “magic bullets” for tumor treatment.However, ADCs still face … Read more

From Single Target to Multidimensional Breakthrough: The New Landscape and Strategic Evolution of Next-Generation ADC Drug Bioanalysis

by
From Single Target to Multidimensional Breakthrough: The New Landscape and Strategic Evolution of Next-Generation ADC Drug Bioanalysis

With the breakthrough progress of novel structures such as bispecific ADCs and dual payload ADCs, ADC drugs have transitioned from “single-target precision strikes” to a new era of “multidimensional collaborative operations.” These innovative designs greatly expand therapeutic potential but also make their molecular structures, mechanisms of action, and in vivo fates unprecedentedly complex. In this … Read more

Comparative Clinical Value of Bispecific ADC vs. Dual Payload ADC

by
Comparative Clinical Value of Bispecific ADC vs. Dual Payload ADC

The following article is sourced from Biotech Investment Notes, authored by Andy. As the technology of ADCs (Antibody-Drug Conjugates) evolves from the “first generation” to the “new generation”, bispecific ADCs and dual payload ADCs have emerged as two major research directions in the industry, breaking through the traditional single-target, single-payload ADCs. Although both are designed … Read more

CrossBridgeBio Breaks Through 30 Years of ADC Challenges with Dual Payload Technology

by
CrossBridgeBio Breaks Through 30 Years of ADC Challenges with Dual Payload Technology

Friends, please click on the above「Medical Intelligence Hardcore Talk」/ Click on the above「 . . .」/ Select「Set as Star」 By 2025, the global ADC (Antibody-Drug Conjugate) market size will exceed $30 billion, yet the confusion among oncologists remains—half of the patients develop resistance during treatment, 15% experience severe side effects due to off-target effects, not … Read more

New Pathway for ADCs – Dual Payload ADCs

by
New Pathway for ADCs - Dual Payload ADCs

Currently, all marketed ADC drug molecules use a single small molecule toxin as the effective payload, but challenges such as drug resistance and limited therapeutic effects still exist. Therefore, clinical chemotherapy regimens often employ combinations of multiple drugs for combination therapy. Considering the clinical efficacy of combination chemotherapy, ADC drugs with two or more effective … Read more

Summary of Dual Payload ADCs at AACR

by
Summary of Dual Payload ADCs at AACR

The AACR is always bustling every year, and this year I am particularly focused on the progress of dual payload ADCs. I have written several articles on this topic before, and just a few days ago, I was discussing with my supervisor that “I haven’t seen any dual payload ADCs advancing to clinical trials yet,” … Read more